Table 1

Clinical assessment, response to infliximab treatment and HMGB1 expression.
Pat
 W
 Sex
 Age (years)
 Disease duration (years)
 CRP
 Medication
 DAS28
 Clinical response
 HMGB1 protein
 HMGB1mRNA






MTX
 Pred
DAS28
 ACR
 ES
 CG
1
 0
 F
 55
 18
 107
 17.5
 5 *
 6.71

1.5
 1

9


38

6.34
 No
 0
 2
 1.5
2
 0
 F
 52
 6
 14
 7.5
 7.5
 6.00

1.5
 1.5

9


15

4.43
 Mod
 20
 1
 0.5
 0
3
 0
 F
 58
 2
 46
 10
7.91

3
 4

9


25

5.41
 Mod
 50
 1
 1.5
 0
4
 0
 F
 57
 4
 7
 10
4.94

2
 2

9


34

4.41
 No
 20
 2
 2
 Up
5
 0
 M
 56
 7
 44
 15
5.95

2
 2.5

9


7

2.90
 G
 70
 3.5
 3
6
 0
 F
 69
 1
 69
 15
 5
 7.39

2
 3

9


7

1.79
 G
 70
 1.5
 2.5
 Up
7
 0
 F
 66
 14
 34
 10
5.64

2
 2

9


16

4.73
 Mod
 0
 1
 0.5
 Down
8
 0
 F
 66
 10
 18
 12.5
4.83

3.5
 4

9


19

4.23
 Mod
 0
 0.5
 2
 Down
9
 0
 M
 25
 0.6
 26
 17.5
 7.5
 5.62

.5
 3

9


25

3.91
 Mod
 20
 3
 4

* Patient 1 also received 150 mg/day cyclosporine before and during the study period.Pat = Patient, W = week, CRP = C-reactive protein, MTX = Methotrexate (mg/week), Pred = Prednisone (mg/day), DAS28 = disease activity score calculated on 28 joints, ACR = American College of Rheumatology, HMGB1 = High-mobility group box chromosomal protein 1, ES = Erik Sundberg, CG = Cecilia Grundtman, F = Female, M = Male, No = Non, Mod = Moderate, G = Good.

Sundberg et al. Arthritis Research & Therapy 2008 10:R33   doi:10.1186/ar2387